Lisa Suennen has spent nearly 30 years as an entrepreneur, venture investor and advisor in the healthcare industry. She currently serves as Senior Managing Director at GE Ventures, leading the firm’s healthcare venture fund. Lisa is also co-founder of CSweetener, a not-for-profit company focused on matching women in and nearing the healthcare C-Suite with mentors who have been there and wish to give back. She is a member of the faculty at the UC Berkeley Haas School of
Business, where for 10 years she has taught classes on venture capital and the changing healthcare economy.
Prior to joining GE Ventures, Lisa operated Venture Valkyrie Consulting for 3 years, advising large corporations around corporate venture capital, new business creation and digital health strategy. Prior to that she spent 15 years as a Partner at Psilos Group, a successful healthcare-focused venture capital firm. Lisa is currently a Board Member of Evidation Health, Health Reveal, Gravie, the Dignity Health Foundation, and Heart To Heart International. She is also on the Advisory Boards of the California Health Care Foundation Innovation Fund, the
American Heart Association Innovation Think Tank, global digital health organization HealthXL and NASA’s Translational Research Institute. Lisa is a Fellow of the inaugural class of the Aspen Institute’s
Health Innovators Fellowship and a member of the Aspen Global Leadership Network. Through her Venture Valkyrie media company, Lisa writes a widely read blog on healthcare and healthcare investing at http://venturevalkyrie.com . She published her
first book in 2013: Tech Tonics, Can Passionate Entrepreneurs Heal Healthcare with Technology, coauthored with Dr. David Shaywitz. Together they also host a popular podcast, also called Tech Tonics, focused on the people and passion at the intersection
of technology and health.
Lisa an M.A. in political science, a B.A. in political science and a B.A. in mass communications, all from the University of California, Berkeley.
As someone who invests in small companies where the culture is really, really important to outcome, it is something I think about almost all of the time when I perform diligence on companies and sit on their boards.
I used to feel like the only person who had ever given any thought to the convergence of tech and devices at medtech conferences. I’m so glad to see the dawn of this new convergence thinking become more and more generally accepted.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
It’s time for entrepreneurs and purchasers to remember that the patient isn’t a component of a healthcare technology plan, they are the point of it.
In his commencement address, Siddhartha Mukherjee exhorted the audience and especially the young graduates to commit to establishing themselves as the “listening generation or Generation L and the power of empathy to figure out the best way to deliver care.
It used to be conventional wisdom that the reason healthcare IT deals were appealing, at least compared to medical devices and biotech, is because they needed far less capital to get to the promised land.
Take a giant step back and you can see that all of the major players are undergoing major material changes in how they define themselves and what they offer to the market. The lines between retail and insurance companies and the pharma and technology industries are melting away.
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
There are over 70,000 genetic tests on the market and up to 10 new ones make an appearance every day. Many offer exciting prospects for healthcare, but numerous companies make claims such as being able to customize a diet to fit one's genomic profile or predicting the athletic abilities of one's children.
Odd bedfellows among pharma and HIT, consumer and HIT, even among tech companies once considered rivals or in different areas of the value chain are coming together and figuring out how dogs and cats can not just get along, but create better, more cuddly offspring.
It’s pretty cool to think about how audacious innovation for space may lead to dramatic innovation here on Earth…how an actual moonshot may result in a terrestrial medical moonshot being achieved.
This year, more than any other, there was an abundance of women at events surrounding the J.P. Morgan Healthcare conference. While the main event featured a mere 20 total women CEOs, the tone on the outside of the Westin St. Francis hotel was somewhat better than in prior years.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
A new study suggests owning a dog can significantly reduce the risk of a cardiovascular-related death. I challenge you to show me any drug or surgery that does the same without side effects and at a comparable cost.
Financial services innovation models aren’t a great proxy for how to disrupt healthcare. Here are a few reasons why.
Lisa Suennen says there should be a book club for innovators and would-be innovators that teaches them the way towards innovation through children’s literature. She offers a peek at what the book list would look like.
This is a cautionary tale for entrepreneurs, whose passion for their work is always so admirable but who don’t always think through this consumer issue to its logical conclusion
Even at the J.P. Morgan Healthcare Conference, the tide seems to have turned. This year, there were at least eight events that I personally heard of that were women-only and overflowing.